ACMT 2020 Annual Scientific Meeting Abstracts – New York, NY

Total Page:16

File Type:pdf, Size:1020Kb

ACMT 2020 Annual Scientific Meeting Abstracts – New York, NY Journal of Medical Toxicology https://doi.org/10.1007/s13181-020-00759-7 ANNUAL MEETING ABSTRACTS ACMT 2020 Annual Scientific Meeting Abstracts – New York, NY Abstract: These are the abstracts of the 2020 American College of Background: Oral cyanide is a potentially deadly poison and has the Medical Toxicology (ACMT) Annual Scientific Meeting. Included here potential for use by terrorists. There is potential for a mass casualty ex- are 174 abstracts that will be presented in March 2020, including research posure scenario, and currently, there are no FDA-approved antidotes spe- studies from around the globe and the ToxIC collaboration, clinically cifically for oral cyanide poisoning. significant case reports describing new toxicologic phenomena, and en- Hypothesis: We hypothesize that animals treated with oral sodium thio- core research presentations from other scientific meetings. sulfate will have a higher rate of survival vs. control in a large animal model of acute, severe, oral cyanide toxicity. Keywords Abstracts, Annual Scientific Meeting, Toxicology Methods: This is a prospective study that took place at the University of Investigators Consortium, Medical Toxicology Foundation Colorado Anschutz Medical Campus. Nine swine (45–55 kg) were in- strumented, sedated, and stabilized. Potassium cyanide (8 mg/kg KCN) in Correspondence: American College of Medical Toxicology (ACMT), saline was delivered as a one-time bolus via an orogastric tube. Three 10645 N. Tatum Blvd, Phoenix, AZ, USA; [email protected] minutes after cyanide, animals who were randomized to the treatment group received sodium thiosulfate (508.2 mg/kg, 3.25 M solution) via Introduction: The American College of Medical Toxicology (ACMT) re- orogastric tube. Survival at 60 minutes after exposure was the primary ceived 223 eligible research abstracts for consideration for presentation at the outcome. We compared survival between treatment and control groups by 2020 Annual Scientific Meeting (ASM), including 107 research studies and log-rank, Mantel–Cox analysis, and trended labs and vital signs. 116 case reports. Each abstract was reviewed in a blinded fashion by at least Results: At baseline and time of treatment, all animals were similar. four research committee members. Each abstract was independently scored Survival at 60 minutes was 100% in treated animals compared to 0% in based on the clinical question, data source, analytic method, results/conclu- the control group (p = 0.0027). Animals in the control group became sion, and clarity of presentation. A total of 177 abstracts were accepted. This apneic and subsequently died by 34.6 ± 15 minutes after cyanide expo- work would not be possible without the hard work and diligence of our sure. Mean arterial pressure was significantly improved between the treat- abstract reviewers: Justin Arnold, Katie Boyle, Jeffrey Brent, Keith ment and control group at study end (p < 0.0001). Blood lactate and Burkhart, Diane Calello, Stephanie Carreiro, James Chenoweth, Neeraj oxygen saturation were also significantly improved between treatment Chhabra, Nick Connors, Kirk Cumpston, Rob Hendrickson, Michelle and control at study end (p =0.0244andp = 0.0281, respectively). Hieger, David Jang, David Juurlink, Louise Kao, Kenneth Katz, Kate Conclusion: Oral administration of sodium thiosulfate improved survival Katzung, Russ Kerns, Andrew King, Kathy Kopec, JoAn Laes, Eric and physiological parameters in a large animal model of oral cyanide Lavonas, Michael Levine, David Liss, Gerald Maloney, Kevin Maskell, toxicity. William Meggs, Andrew Monte, Elissa Moore, Mark Mycyk, Travis Olives, Patricia Rosen, Evan Schwarz, Daniel Sessions, Samuel Stellpflug, 002. Outbreak of Hypoglycemia from Counterfeit “V8” Male Sexual Mark Su, Manoj Tyagi, Shawn Varne, Steven Walsh, Richard Wang, Sage Enhancement Supplements Wiener, Brandon Wills, and Luke Yip. Equally significant is the contribution of the ACMT staff (Adrienne Dunavin, Dana Karshenas, and Lizzy Nguyen) John W Downs1, Landon R Mueller1,OkeyFUtah2, Brandon K Wills1, who led the process. Congratulations to all the contributors whose work will Kirk L Cumpston1, S. Rutherfoord Rose1 be presented in New York. 1Virginia Commonwealth University Health System, Richmond, VA, USA. 2Richmond City Health District, Richmond, VA, USA We look forward to seeing you there. Background: Over-the-counter male sexual enhancement supplements may Jon B. Cole, MD, FACMT, Abstract Review Chair; Christine Murphy, contain undisclosed prescription pharmaceuticals such as phosphodiesterase- MD, FACMT, Abstract Review Co-Chair; Maryann Amirshahi, PharmD, 5 inhibitors. For unclear reasons, other pharmaceutical contaminants may be MD, MPH, PhD, FACMT, Chair, ACMT Research Committee present. This report describes an investigation of an outbreak of unexplained hypoglycemia associated with the use of an adulterated, counterfeit male ACMT 2020 Annual Scientific Meeting Abstracts – New York, NY sexual enhancement supplement called “V8.” Hypothesis: “V8” male sexual enhancement supplement contains a sul- Day 1: Platforms, Abstracts 001–004 fonylurea contaminant resulting in symptomatic hypoglycemia. Methods: This was an urgent prospective cohort study conducted as an 001. Efficacy of Oral Sodium Thiosulfate for Acute, Severe Oral outbreak investigation in conjunction with local and state public health Cyanide Toxicity in Swine authorities. Cases were defined as persons with unexplained hypoglyce- mia who reported use of “V8” male enhancement supplement. Cases Patrick C Ng1, Tara B Hendry-Hofer2, Joseph K Maddry3, Vikhyat S were obtained through calls to the Virginia Poison Center. Case discovery Bebarta2 and dissemination of information included health care facility notifica- 1Brooke Army Medical Center, Fort Sam Houston, TX, USA. 2University tion, press release, and social media posts. Biologic samples and product of Colorado Anschutz Medical Campus, Aurora, CO, USA. 3En Route samples were submitted to the Virginia Department of Health Laboratory Care and Research Center, Fort Sam Houston, TX, USA for analysis for culprit contaminants. J. Med. Toxicol. Results: Seven cases of unexplained symptomatic hypoglycemia associ- 1Department of Medicine, University of Maryland Medical School, ated with V8 male enhancement supplement use were reported to the Baltimore, MD, USA. 2University of Maryland A. James Clark School Virginia Poison Center over a 4-week period. All cases were treated with of Engineering, College Park, MD, USA. 3Department of Surgery, supplemental dextrose and octreotide. All were admitted for a minimum University of Maryland Medical School, Baltimore, MD, USA. of 24 hours of observation. Lowest recorded blood glucose concentra- 4Maryland Poison Center, Baltimore, MD, USA tions ranged from 26 to 48 mg/dL (median 32 mg/dL). Median hospital length of stay was 2 days. Product samples were obtained from retail Background: Extracorporeal removal of toxins is limited by the amount locations as well as from cases. Product testing at the state public health of blood which can be processed over a given time period. Extracorporeal laboratory confirmed glyburide estimated at 90–100 mg per tablet, as well membrane oxygenation (ECMO) processes blood roughly ten times faster as sildenafil ranging 55–156 mg per tablet. Three cases had serum sulfo- than conventional hemodialysis. We recently demonstrated that high- nylurea screens performed and all three were positive for glyburide. No volume hemofiltration in a patient undergoing ECMO is achievable, of- adverse effects of sildenafil were reported. fering the possibility of markedly increased extracorporeal toxin Conclusion: Counterfeit male sexual enhancement supplements contained elimination. prescription sildenafil and glyburide, which produced life-threatening hypo- Hypothesis: A high-volume hemofiltration system within an ECMO cir- glycemia. These patients required admission and treatment of prolonged, cuit allows for superior extracorporeal toxin removal compared to con- refractory hypoglycemia with dextrose and supplemental octreotide. ventional hemodialysis. Methods: This is an in vitro single-compartment model of an ECMO 003. Assessment of the Overdosage Section of Labeling for Drugs circuit with an in-line high-volume hemofiltration system. A primary Highly Associated with Drug Poison Fatalities closed circuit with 5 L of 0.9% saline and 6.8 mg/L flecainide acetate (approximating a 5000-mg ingestion in an 80-kg person) was connected Keith K Burkhart, Eric Brodsky to Revaclear© hemodialysis filters attached in parallel. A centrifugal Food and Drug Administration, Silver Spring, MD, USA blood pump (CentriMag©) drove the primary circuit at a flow rate of 4 L/minute, while two separate pumps were used to remove effluent Background: FDA regulations require the overdosage section of labeling and infuse replacement fluid (saline). A trial with two hemodialysis filters for human prescription drugs be updated when new information becomes was performed, followed by a second trial with eight filters. Flecainide available that causes the labeling to become inaccurate, false, or mislead- concentration of samples drawn periodically was determined with ing [21 CFR 201.57(c)(11) and 21 CFR 201.56(a)(2)]. ultraviolet–visible spectroscopy, and removal rates were calculated. Methods: We compared the overdosage management recommendations Results: In the two-filter circuit, effluent flow rate of 0.4 L/minute was in the overdosage section of 29 selected labeling to overdosage manage-
Recommended publications
  • Medical Cannabis Q&A
    Medical Cannabis Q&A 1. What is medical cannabis? The term “medical cannabis” is used to describe products derived from the whole cannabis plant or its extracts containing a variety of active cannabinoids and terpenes, which patients take for medical reasons, after interacting with and obtaining authorization from their health care practitioner. 2. What are the main active ingredients? The chemical ingredients of cannabis are called cannabinoids. The two main therapeutic ones are: THC:CBD a. Tetrahydrocannabinol (THC) is a partial agonist of CB1 and CB2 receptors. It is psychoactive and produces the euphoric effect. Each cannabis product will contain THC and CBD, however b. Cannabidiol (CBD) has a weak affinity for CB1 and CB2 receptors and appears the THC: CBD ratio will differ to exert its activity by enhancing the positive effects of the body’s endogenous depending on the product. cannabinoids. 3. Why do patients take it? Medical cannabis may be used to alleviate symptoms for a variety of conditions. It has most commonly been used in neuropathic pain and other chronic pain conditions. There is limited, but developing clinical evidence surrounding its safety and efficacy, and it does not currently have an approved Health Canada indication. 4. How do patients take it? Cannabis can be smoked, vaporized, taken orally, sublingually, topically or rectally. Different routes of administration will result in different pharmacokinetic and pharmacodynamic properties of the drug. 5. Is it possible to develop dependence on medical cannabis? Yes, abrupt discontinuation after long-term use may result in withdrawal symptoms. Additionally, chronic use may result in psychological dependence.
    [Show full text]
  • EMBASE Find Quick, Relevant Answers to Your Biomedical Questions
    EMBASE Find quick, relevant answers to your biomedical questions Piotr Golkiewicz Solution Sales Manager Life Sciences Central and Eastern Europe and Russia Embase® is a registered trademark of Elsevier BV. WHAT IS EMBASE? THE WORLD’S MOST COMPREHENSIVE BIOMEDICAL RESEARCH TOOL Reliable and authoritative content to help the drug and drug-related research community advance new biomedical and pharmaceutical discoveries. Confidence Find all relevant articles that may not otherwise be found by using alternative databases Deep Biomedical Indexing All relevant, up-to-date, biomedical information from the research literature Precise Retrieval Deep and focused research using the most powerful retrieval tools 2 HOW EMBASE DELIVERS VALUE ...by including literature and Conference Scientific In Press We make sure you information resources in a proceedings Journals (unpublished) don’t miss any timely manner biomedical literature ...by reading full-text to The only close identify drugs, diseases, Deep indexing using own taxonomy alternative is adverse affects, clinical (EMTREE) reading trials, drug trade names etc. all the articles ...by enabling advanced search filters to drill down a Very powerful Good precision and comprehensive search to a recall balance relevant and manageable record Search Environment set ...by allowing users to automate Automation and searching and result management documentation E-mail Alerting API Interoperability 3 EMBASE CONTENT 4 EMBASE IS AS COMPREHENSIVE AS POSSIBLE SOURCE TEXT MINING EMBASE SCOPUS Effort / tools required / tools Effort PUBMED GOOGLE 0 % 50 % 100 % Percentage of relevant articles retrieved 5 COMPREHENSIVE CONTENT COVERAGE ON AVERAGE >5000 RECORDS ADDED EACH WORKDAY! Embase: Now covers over 8,400 journals Indexed at Embase (over 5,700 titles) Indexed by MEDLINE (e.g.
    [Show full text]
  • TREATED with CRUELTY: ABUSES in the NAME of DRUG REHABILITATION Remedies
    TREATED WITH CRUELTY ABUSES IN THE NAME OF DRUG REHABILITATION Copyright © 2011 by the Open Society Foundations All rights reserved, including the right to reproduce this book or portions thereof in any form. For more information, contact: International Harm Reduction Development Program Open Society Foundations www.soros.org/harm-reduction Telephone: 1 212 548 0600 Fax: 1 212 548 4617 Email: [email protected] Cover photo: A heroin user stands in the doorway at the Los Tesoros Escondidos Drug Rehabilita- tion Center in Tijuana, Mexico. Addiction treatment facilities can be brutal and deadly places in Mexico, where better, evidence-based alternatives are rarely available or affordable. (Sandy Huf- faker/ Getty Images) Editing by Roxanne Saucier, Daniel Wolfe, Kathleen Kingsbury, and Paul Silva Design and Layout by: Andiron Studio Open Society Public Health Program The Open Society Public Health Program aims to build societies committed to inclusion, human rights, and justice, in which health-related laws, policies, and practices reflect these values and are based on evidence. The program works to advance the health and human rights of marginalized people by building the capacity of civil society leaders and organiza- tions, and by advocating for greater accountability and transparency in health policy and practice. International Harm Reduction Development Program The International Harm Reduction Development Program (IHRD), part of the Open Society Public Health Program, works to advance the health and human rights of people who use drugs. Through grantmaking, capacity building, and advocacy, IHRD works to reduce HIV, fatal overdose and other drug-related harms; to decrease abuse by police and in places of detention; and to improve the quality of health services.
    [Show full text]
  • 2020 DAID Conference Tentative Schedule and Agenda Online
    Tentative 2020 Conference Schedule (As of 7/24/20) Please note that this schedule is suBject to change All times are EST 2020 Conference Schedule Thursday, August 6, 2020 11:00 AM 12:00 PM Opening Ceremony & Keynote Presentation 12:00 PM 12:45 PM Exposition Hall & Networking Linking SFST Impairment to Individual What You Need to Know About Today's Drug Do You Have Skin in the Game? 12:45 PM 1:45 PM Driving Tasks Mule James Camp Travis Herbert Mike Snyders & Tim Cardwell 1:45 PM 2:00 PM Break To Draw or Not to Draw: Why Your DRE Traditional and Designer Benzodiazepines Building Your DRE Program Through Program Should Include LE Phlebotomists 2:00 PM 3:00 PM in Impaired Driving Casework Education and Awareness Jennifer Cifaldi, Nicholas Knoll, & Kemp Dr. Barry Logan & Ayako Hosokawa Frank Enko Layden 3:00 PM 3:15 PM Break Overcoming Defense Challenges 3:15 PM 4:45 PM Clay Abbott, Beth Barnes, & Jeff SIfers 4:45 PM 5:30 PM Networking Discussions on Contemporary Issues Friday, August 7, 2020 Public-Private Ventures, Curbing Alcohol Traffic Safety as a Critical Part of an Agency's NHTSA Update 11:00 AM 12:00 PM and Drug Impaired Driving Patrol Strategy Amy Berning, Bill O'Leary, & Christine Frank Ed Hutchison, John Whetsel, & Glenn Davis Howard Hall & Cara Jacobs 12:00 PM 1:00 PM Exposition Hall & Networking Beyond Eye Movements: How Intoxication Affects Visual Perception 1:00 PM 2:15 PM Dr. Karl Citek 2:15 PM 2:30 PM Break Responsibility.org: A Proactive Partner in Eliminating Impaired Driving/Safe Night Take a Breath and Reconstruct Winning the Case with Testimony 2:30 PM 3:30 PM Out Chuck Matson Christine Circo Darrin Grondel & John Mastoras 3:30 PM 3:45 PM Break Courtroom Testimony from a Judge's Dusted in Houston: Spike in PCP-Driving Noteworthy Supreme Court Cases 3:45 PM 4:45 PM Perspective Cases Kendrick Stecker Hon.
    [Show full text]
  • A Case of Attempted Suicide by Cerbera Odollam Seed Ingestion
    Hindawi Case Reports in Critical Care Volume 2020, Article ID 7367191, 5 pages https://doi.org/10.1155/2020/7367191 Case Report A Case of Attempted Suicide by Cerbera odollam Seed Ingestion Michelle Bernshteyn , Steven H. Adams, and Kunal Gada SUNY Upstate Medical University, 750 E Adams St., Syracuse, NY 13210, USA Correspondence should be addressed to Michelle Bernshteyn; [email protected] Received 3 March 2020; Revised 2 June 2020; Accepted 4 June 2020; Published 15 June 2020 Academic Editor: Ricardo Jorge Dinis-Oliveira Copyright © 2020 Michelle Bernshteyn et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. We report a case of attempted suicide by Cerbera odollam seed ingestion by a transgender patient who was successfully treated at our hospital. While the C. odollam plant has multiple practical and ornamental functions, its seeds have traditionally been utilized for suicidal and homicidal purposes in many parts of the world. Physicians should be aware of the presentation, diagnosis, and treatment of C. odollam ingestion given the current ease of availability of these seeds in the United States and the increased reports of suicide attempts. 1. Introduction with a junctional rhythm and therefore received a total of 10 vials of Digibind (digoxin immune fab). She denied any head- Indigenous to India and Southeast Asia, Cerbera odollam, ache, visual disturbances, chest pain, palpitations, shortness “ ” also known as pong-pong, or suicide tree, yields highly car- of breath, abdominal tenderness, diarrhea, or constipation.
    [Show full text]
  • Multi-Class Determination of 64 Illicit Compounds in Dietary Supplements Using Liquid Chromatography–Tandem Mass Spectrometry
    molecules Article Multi-Class Determination of 64 Illicit Compounds in Dietary Supplements Using Liquid Chromatography–Tandem Mass Spectrometry Dasom Shin, Hui-Seung Kang *, Hyungsoo Kim and Guiim Moon New Hazardous Substances Division, Department of Food Safety Evaluation, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Osong, Cheongju 28159, Korea; [email protected] (D.S.); [email protected] (H.K.); [email protected] (G.M.) * Correspondence: [email protected] Received: 11 August 2020; Accepted: 17 September 2020; Published: 24 September 2020 Abstract: In this work, liquid chromatography–tandem mass spectrometry (LC-MS/MS) method was developed and validated for screening and confirmation of 64 illicit compounds in dietary supplements. The target compounds were illegally used pharmaceutical drugs, prohibited compounds, and not authorized ingredients for different therapeutics (sexual enhancement, weight loss, muscular strengthening, and relaxing products). The validation procedure was performed to evaluate selectivity, linearity, limit of detection (LOD), limit of quantification (LOQ), accuracy, and precision according to the Association of Official Analytical Chemists guidelines. The linearity was >0.98 in the range of 1 1 0.5–200 µg L− . The LOQs were in the range 1–10 µg kg− for all target compounds. The accuracy (expressed as recovery) was 78.5–114%. The precision (expressed as the relative standard deviation) was below 9.15%. The developed method was applied for the determination of illicit compounds in dietary supplements collected from websites. As a result, the total detection rate was 13.5% (27 samples detected in 200 samples). The concentrations of detected samples ranged from 0.51 1 to 226 mg g− .
    [Show full text]
  • Réglementation De La Pharmacie
    R E C U E I L D E T E X T E S S U R L A P H A R M A C I E Mis à jour le 13 février 2017 par l’Inspection de la pharmacie P R É A M B U L E La réglementation relative à la pharmacie en vigueur en Nouvelle-Calédonie résulte de la coexistence des dispositions adoptées par la Nouvelle-Calédonie au titre de ses compétences en matières d’hygiène publique, de santé et de professions de la pharmacie1, et de celles adoptées par l’Etat au titre de ses compétences en matières de garanties des libertés publiques, de droit civil et de droit commercial2. Sur le contenu du recueil En 1954, la Nouvelle-Calédonie s’est vue étendre les articles L. 511 à L. 520 et L. 549 à L. 665 de l’ancien Livre V relatif à la Pharmacie du code de la santé publique métropolitain par la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du Code de la santé publique relatives à l'exercice de la pharmacie3, dont les modalités d’application ont été fixées par le décret modifié n° 55-1122 du 16 août 1955 fixant les modalités d'application de la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du code de la santé publique relatives à l'exercice de la pharmacie4. Depuis sont intervenues la loi- cadre Defferre5, la loi référendaire de 19886 et la loi organique n° 99-209 du 19 mars 1999 dont les apports ont eu pour résultat le transfert de ces articles de la compétence de l’Etat à la compétence de la Nouvelle-Calédonie, permettant à celle-ci de s’en approprier et de les modifier à sa guise par des délibérations du congrès de la Nouvelle-Calédonie7.
    [Show full text]
  • Phytochemical Analysis, Antioxidant Assay and Antimicrobial Activity in Leaf Extracts of Cerbera Odollam Gaertn
    Pharmacogn J. 2018; 10(2): 285-292 A Multifaceted Journal in the field of Natural Products and Pharmacognosy Original Article www.phcogj.com | www.journalonweb.com/pj | www.phcog.net Phytochemical Analysis, Antioxidant Assay and Antimicrobial Activity in Leaf Extracts of Cerbera odollam Gaertn Abinash Sahoo, Thankamani Marar* ABSTRACT Introduction: In the current study, methanol and aqueous extracts of leaf of Cerbera odollam Gaertn were screened for its antibacterial, antifungal, phytochemicals and antioxidant ac- tivities. Phytochemical constituents were investigated both qualitatively and quantitatively. Methods: The leaf extracts of Cerbera odollam Gaertn were prepared by drying and extracted using Soxhlet apparatus into methanol and aqueous media, which were subjected to phyto- chemical screening. Total phenols, tannins, flavanols, alkaloids and its antioxidant activity were determined using spectroscopic techniques. Antimicrobial activity were determined using well diffusion method. Results: Aqueous extract exhibits higher content of phenols, tannins, flavanols and alkaloids, whereas methanol extract exhibits higher content of anthocyanin and cardiac glycoside respectively. Aqueous extract exhibits higher inhibitory concentration (IC %) value for DPPH (2, 2-Diphenyl-1-picrylhydrazyl) and H2O2 radical scavenging assay and reduc- ing power (RP) assay. The methanol extracts exhibited higher inhibitory concentration (IC %) value in SO and NO radical scavenging assay, exhibiting antioxidant properties in five antioxi- dant models that were investigated. The methanol extract showed some antibacterial activity against Bacillus subtilis, Staphylococcus aureus, Salmonella typhi and Escherichia coli with inhibitory zone ranging from 2 mm to 3 mm, whereas the aqueous extract showed no activity. Abinash Sahoo, High antifungal activity was found against Saccharomyces cerevisiae and Candida albicans for methanol extract and moderate for aqueous extract with inhibitory zone ranging from 9mm Thankamani Marar* to 26 mm.
    [Show full text]
  • CLINICA CHIMICA ACTA International Journal of Clinical Chemistry and Diagnostic Laboratory Medicine
    CLINICA CHIMICA ACTA International Journal of Clinical Chemistry and Diagnostic Laboratory Medicine AUTHOR INFORMATION PACK TABLE OF CONTENTS XXX . • Description p.1 • Audience p.1 • Impact Factor p.1 • Abstracting and Indexing p.2 • Editorial Board p.2 • Guide for Authors p.4 ISSN: 0009-8981 DESCRIPTION . Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnosticapplication of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal's scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.
    [Show full text]
  • Veterinary Toxicology
    GINTARAS DAUNORAS VETERINARY TOXICOLOGY Lecture notes and classes works Study kit for LUHS Veterinary Faculty Foreign Students LSMU LEIDYBOS NAMAI, KAUNAS 2012 Lietuvos sveikatos moksl ų universitetas Veterinarijos akademija Neužkre čiam ųjų lig ų katedra Gintaras Daunoras VETERINARIN Ė TOKSIKOLOGIJA Paskait ų konspektai ir praktikos darb ų aprašai Mokomoji knyga LSMU Veterinarijos fakulteto užsienio studentams LSMU LEIDYBOS NAMAI, KAUNAS 2012 UDK Dau Apsvarstyta: LSMU VA Veterinarijos fakulteto Neužkre čiam ųjų lig ų katedros pos ėdyje, 2012 m. rugs ėjo 20 d., protokolo Nr. 01 LSMU VA Veterinarijos fakulteto tarybos pos ėdyje, 2012 m. rugs ėjo 28 d., protokolo Nr. 08 Recenzavo: doc. dr. Alius Pockevi čius LSMU VA Užkre čiam ųjų lig ų katedra dr. Aidas Grigonis LSMU VA Neužkre čiam ųjų lig ų katedra CONTENTS Introduction ……………………………………………………………………………………… 7 SECTION I. Lecture notes ………………………………………………………………………. 8 1. GENERAL VETERINARY TOXICOLOGY ……….……………………………………….. 8 1.1. Veterinary toxicology aims and tasks ……………………………………………………... 8 1.2. EC and Lithuanian legal documents for hazardous substances and pollution ……………. 11 1.3. Classification of poisons ……………………………………………………………………. 12 1.4. Chemicals classification and labelling ……………………………………………………… 14 2. Toxicokinetics ………………………………………………………………………...………. 15 2.2. Migration of substances through biological membranes …………………………………… 15 2.3. ADME notion ………………………………………………………………………………. 15 2.4. Possibilities of poisons entering into an animal body and methods of absorption ……… 16 2.5. Poison distribution
    [Show full text]
  • Twelve Cases of Drug-Induced Blepharospasm Improved Within 2 Months of Psychotropic Cessation
    Drug, Healthcare and Patient Safety Dovepress open access to scientific and medical research Open Access Full Text Article CASE SERIES Twelve cases of drug-induced blepharospasm improved within 2 months of psychotropic cessation Yuko Emoto1 Background: To determine whether psychotropic cessation in patients with drug-induced Hirofumi Emoto2 blepharospasm improves motor symptoms. Eriko Oishi1 Methods: In patients with drug-induced blepharospasm, we withdrew part or all of their psy- Syunichi Hikita1 chotropic medication and assessed motor symptoms using the Jankovic rating scale (0 = none, Masato Wakakura1 1 = noticeable, 2 = mild, 3 = moderate, 4 = severe) at first presentation and after cessation. Results: Twelve patients (eleven women and one man, mean age 60.4 years) were enrolled. 1Division of Neuro-Ophthalmology, Psychotropics were administered before the onset of blepharospasm in all patients. The mean Inouye Eye Hospital, Tokyo; 2Department of Ophthalmology and duration of treatment with psychotropic medication was 47.3 (range 3–120) months. Jankovic Visual Science, Tokyo Medical and rating scale at initial presentation was 3 in eleven patients and 2 in one patient. After cessation, Dental University, Graduate School of Medicine, Tokyo, Japan blepharospasm started to improve in all cases within 2 months (average 3.9 weeks). While the effect of psychotropic cessation was variable, the symptoms eventually improved to more than 2 on the rating scale. Three of the twelve patients underwent a single botulinum neurotoxin injection and were withdrawn from therapy after cessation. Conclusion: Psychotropic drugs can cause blepharospasm in some cases. Clinicians should consider reducing psychotropic medication as far as possible in patients with blepharospasm taking these agents.
    [Show full text]
  • ETIZOLAM Critical Review Report Agenda Item 4.13
    ETIZOLAM Critical Review Report Agenda Item 4.13 Expert Committee on Drug Dependence Thirty-ninth Meeting Geneva, 6-10 November 2017 39th ECDD (2017) Agenda item 4.13 Etizolam Page 2 of 20 39th ECDD (2017) Agenda item 4.13 Etizolam Contents Acknowledgements.................................................................................................................................. 5 Summary...................................................................................................................................................... 6 1. Substance identification ....................................................................................................................... 7 A. International Nonproprietary Name (INN).......................................................................................................... 7 B. Chemical Abstract Service (CAS) Registry Number .......................................................................................... 7 C. Other Chemical Names ................................................................................................................................................... 7 D. Trade Names ....................................................................................................................................................................... 7 E. Street Names ....................................................................................................................................................................... 8 F. Physical Appearance
    [Show full text]